Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioreactor Controls-III01:22

Bioreactor Controls-III

Strain improvement is a foundational strategy in industrial microbiology aimed at maximizing microbial productivity, particularly because natural isolates typically yield commercially valuable products in very low concentrations. Although optimizing the culture medium and environmental conditions can improve yields, these adjustments are inherently limited by the organism’s genetic potential. As a result, the focus shifts toward genetic modifications to enhance biosynthetic capacity. The...
Biofuels01:25

Biofuels

The microbial conversion of organic matter into biofuels holds potential as a renewable energy source. Among biofuel sources, microalgae are recognized as a highly efficient and adaptable feedstock for biodiesel production, owing to their rapid biomass accumulation, elevated lipid productivity, and capacity to proliferate in diverse aquatic systems, including freshwater, marine, and wastewater habitats. Unlike terrestrial crops, microalgae do not compete for land and can achieve significantly...
Production of Biopesticides01:18

Production of Biopesticides

Biopesticides offer a sustainable alternative to chemical pesticides, utilizing microbial agents to control agricultural pests. Bacillus thuringiensis (Bt) is a widely employed bacterium known for its potent insecticidal activity. Bt biopesticides are favored for their specificity to insect pests, minimal environmental impact, and natural degradability.Mechanism of Bt Toxin Action Bt produces insecticidal crystal (Cry) proteins during its sporulation phase. These proteins form parasporal...
Synthetic Biology02:55

Synthetic Biology

Synthetic biology is an interdisciplinary science that involves using principles from disciplines such as engineering, molecular biology, cell biology, and systems biology. It involves remodeling existing organisms from nature or constructing completely new synthetic organisms for applications such as protein or enzyme production, bioremediation, value-added macromolecule production, and the addition of desirable traits to crops, to name a few.
Golden rice
Golden rice is a genetically modified...
Bioremediation00:46

Bioremediation

Bioremediation is the use of prokaryotes, fungi, or plants to remove pollutants from the environment. This process has been used to remove harmful toxins in groundwater as a byproduct of agricultural run-off and also to clean up oil spills.
The Central Dogma01:20

The Central Dogma

The central dogma explains the flow of genetic information from DNA nucleotides to the amino acid sequence of proteins.
RNA is the Missing Link Between DNA and Proteins
In the early 1900s, scientists discovered that DNA stores all the information needed for cellular functions and that proteins perform most of these functions. However, the mechanisms of converting genetic information into functional proteins remained unknown for many years. Initially, it was believed that a single gene is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adaptive Biomedical Innovation.

Clinical pharmacology and therapeutics·2016
Same author

Pharmacotherapy for Neurodegenerative Diseases: Are We Approaching the Tipping Point?

Clinical pharmacology and therapeutics·2015
Same author

Recent trends and success factors in reducing the lag time to approval of new drugs in Japan.

Clinical pharmacology and therapeutics·2014
Same author

The biotechnology innovation machine: a source of intelligent biopharmaceuticals for the pharma industry--mapping biotechnology's success.

Clinical pharmacology and therapeutics·2014
Same author

A proposal for integrated efficacy-to-effectiveness (E2E) clinical trials.

Clinical pharmacology and therapeutics·2013
Same author

Advancing the science of pharmacovigilance.

Clinical pharmacology and therapeutics·2013
Same journal

Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

Clinical pharmacology and therapeutics·2026
Same journal

Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

Clinical pharmacology and therapeutics·2026
Same journal

Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

Clinical pharmacology and therapeutics·2026
Same journal

Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

Clinical pharmacology and therapeutics·2026
Same journal

Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory Review.

Clinical pharmacology and therapeutics·2026
Same journal

Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data.

Clinical pharmacology and therapeutics·2026
See all related articles

Related Experiment Video

Updated: May 8, 2026

BioMEMS: Forging New Collaborations Between Biologists and Engineers
07:26

BioMEMS: Forging New Collaborations Between Biologists and Engineers

Published on: November 1, 2007

Reinventing bioinnovation.

K I Kaitin, P K Honig

    Clinical Pharmacology and Therapeutics
    |August 22, 2013
    PubMed
    Summary
    This summary is machine-generated.

    The drug development ecosystem is shifting as scientific advances struggle to become new medicines. Traditional models are being replaced by innovative approaches to accelerate bioinnovation and bring therapeutics to market faster.

    More Related Videos

    Genetic Engineering of an Unconventional Yeast for Renewable Biofuel and Biochemical Production
    10:10

    Genetic Engineering of an Unconventional Yeast for Renewable Biofuel and Biochemical Production

    Published on: September 20, 2016

    Bridging the Bio-Electronic Interface with Biofabrication
    16:38

    Bridging the Bio-Electronic Interface with Biofabrication

    Published on: June 6, 2012

    Related Experiment Videos

    Last Updated: May 8, 2026

    BioMEMS: Forging New Collaborations Between Biologists and Engineers
    07:26

    BioMEMS: Forging New Collaborations Between Biologists and Engineers

    Published on: November 1, 2007

    Genetic Engineering of an Unconventional Yeast for Renewable Biofuel and Biochemical Production
    10:10

    Genetic Engineering of an Unconventional Yeast for Renewable Biofuel and Biochemical Production

    Published on: September 20, 2016

    Bridging the Bio-Electronic Interface with Biofabrication
    16:38

    Bridging the Bio-Electronic Interface with Biofabrication

    Published on: June 6, 2012

    Area of Science:

    • Biopharmaceutical research and development
    • Translational science
    • Drug discovery and development

    Background:

    • The bioinnovation landscape faces significant challenges in translating scientific understanding into new therapeutics.
    • Traditional drug development paradigms are proving insufficient to meet current needs.
    • Adaptation is required from drug developers, regulators, academic institutions, and government research organizations.

    Discussion:

    • Exploring the seismic shifts in the bioinnovation ecosystem.
    • Examining the need for novel drug development models.
    • Addressing the gap between scientific discovery and therapeutic application.

    Key Insights:

    • Current bioinnovation models are inadequate for translating scientific progress into medicines.
    • A paradigm shift towards more efficient drug development is necessary.
    • Collaboration across sectors is crucial for overcoming development hurdles.

    Outlook:

    • The future of bioinnovation necessitates more agile and efficient development pathways.
    • Continued exploration of new models is essential for advancing therapeutic options.
    • This issue highlights critical changes impacting the future of medicine development.